AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas –immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X, Facebook, Instagram, YouTube, LinkedIn and Tik Tok.

1 North Waukegan Road
North Chicago, IL 60064

Visit website

Stock Symbol: ABBV
Stock Exchange: NYSE

Together, we break through.

Our principles are at the Heart of our Company. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

How we work with each other and achieve results matters. That’s why we’ve been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 Great Place to Work and Top Employer lists and FORTUNE “100 Best Companies to Work For.”

Click here to learn more about our principles.

NEWS

Business

New Report Expresses Optimism Over Current State of Alzheimer’s Drug Development

Noting that from 1998 to 2017 there have been about 146 failed shots at developing drugs for Alzheimer’s disease, PhRMA released a report on the state of the industry. This would not lead most people to think there are many reasons to be optimistic about Alzheimer’s disease research, but the report does believe there are good reasons to be.

November 30, 2018

3 min read

Mark Terry

FDA

AbbVie and Genentech Snag Accelerated Approval for Venclexta in AML

AbbVie could be eyeing another potential billion dollars of annual revenue following the accelerated approval of Venclexta for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older or who cannot tolerate intensive chemotherapy.

November 26, 2018

2 min read

Alex Keown

Business

One Busy Week for AbbVie: Hepatitis C, Fibroids, Alzheimer’s & Parkinson’s, and Generic Criticism

AbbVie presented additional data from two Phase III clinical trials in women with uterine fibroids. In a big news week for the company, what else is AbbVie up to?

November 15, 2018

4 min read

Mark Terry

Business

AbbVie’s Mavyret Demonstrates Sky-High Cure Rates in Hepatitis C

Chicago-based AbbVie just announced new data for its Mavyret (glecaprevir/pibrentasvir), a pan-genotypic treatment for chronic HCV in treatment-naive patients with compensated cirrhosis.

November 14, 2018

3 min read

Mark Terry

BioMidwest

Updated: Amgen Co-Founds Fund to Help Conejo Valley Shooting Victims; Donates to Wildfire Victims

The fund will be administered through the Ventura County Community Foundation. Officials indicate that 100 percent of the funds will go to help victims’ families. The Foundation is calling for additional donations.

November 8, 2018

3 min read

Mark Terry

Genetown

15 Massachusetts Life Science Companies That Spend the Most on R&D

Boston Business Journal recently created a list of 15 Massachusetts life science companies that in their third-quarter reports, allocated the highest percentage of total costs to research and development. Here’s a look.

November 8, 2018

4 min read

Mark Terry

Business

Biogen Ups Investment in Biosimilar Drug Maker Samsung Bioepis by $700 Million

Cambridge, Mass.-based Biogen exercised its option to acquire additional shares of South Korea’s Samsung Bioepis. Samsung Bioepis focuses on developing biosimilar drugs and is a joint venture between Samsung Biologics and Biogen formed in 2012.

November 7, 2018

3 min read

Mark Terry

Why Bristol-Myers' Future is Highly Dependent on T

FDA

BMS’ Empliciti Garners a New FDA Indication for Multiple Myeloma

Joseph Eid, head of medical at BMS, said Empliciti in combination with pomalidomide and dexamethasone has provided proof that the medication can extend the time a patient can live without the worsening of his or her disease.

November 7, 2018

3 min read

Alex Keown

Business

AbbVie Follows Trend of Big Pharma Setting Office-Labs in Biotech Clusters

In what appears to be a trend, big pharma company AbbVie is leasing 479,000 square feet of space inBioMed Realty’s Gateway of Pacific project in South San Francisco.

November 2, 2018

3 min read

Mark Terry

JOBS